NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD
Taking everything into account, MYGN scores 3 out of 10 in our fundamental rating. MYGN was compared to 560 industry peers in the Biotechnology industry. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, MYGN is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -12.39% | ||
ROE | -18.16% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 69.89% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.06 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.36 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.82 | ||
Quick Ratio | 1.65 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 37.82 | ||
Fwd PE | 25.38 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
4.16
-0.17 (-3.93%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 37.82 | ||
Fwd PE | 25.38 | ||
P/S | 0.46 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.55 | ||
P/tB | 2.52 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -12.39% | ||
ROE | -18.16% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 69.89% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.06 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 48.53% | ||
Cap/Sales | 3.55% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.82 | ||
Quick Ratio | 1.65 | ||
Altman-Z | 0.36 |